ClearNote Health Raises $52 Million Series D to Advance AI-Powered…

Team S · 2026-05-27T15:03:08.000Z

San Diego-based precision diagnostics company ClearNote Health has secured $52 million in Series D funding to accelerate commercialization of its noninvasive cancer detection technologies and expand global access to early cancer screening solutions. The round was led by founding investor Mattias Westman alongside a major global long-only active investment manager, with participation from former Citigroup CEO Sandy Weill, ClearNote Health co-founder Dr. Stephen Quake, a large Seattle-based family office, and additional institutional investors. Founded around breakthrough research from Stanford University, ClearNote Health develops advanced epigenomic diagnostics capable of detecting difficult-to-diagnose cancers through blood-based testing. The company’s proprietary Virtuoso™ epigenomics platform combines artificial intelligence, genomics, and bioinformatics to identify active biological signals associated with cancer development. ClearNote Health’s Avantect® platform focuses initially on pancreatic and ovarian cancer detection - two cancers where early diagnosis dramatically improves survival outcomes. The company says its blood-based screening systems may enable detection earlier than conventional diagnostic methods in high-risk patient populations. The startup also announced the appointment of clinical diagnostics veteran Kevin Keegan as President and COO. Keegan previously held senior leadership roles at Illumina, BD, and Hologic, where he helped scale major oncology diagnostic platforms globally. According to the company, the fresh capital will support commercial expansion, operational scaling, product development, clinical study execution, and broader deployment of its early cancer detection portfolio. ClearNote Health’s multi-cancer detection platform was recently selected as one of only two blood-based technologies for the US National Cancer Institute’s Vanguard Study. The funding reflects accelerating investor interest in AI-powered precision medicine, liquid biopsy technologies, genomics infrastructure, and preventive healthcare systems capable of improving early cancer detection at population scale.

Member Login Get Access

ClearNote Health Raises $52 Million Series D to Advance AI-Powered… | Newnex